F4 Pharma GmbH

F4 Pharma, a clinical-stage biopharmaceutical company developing F06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, FX06 is a substance discovered and developed in the Medical University of Vienna and has a dual mode of action: it is reducing the capillary leak and has anti-inflammatory efficacy. In Covid-19 by reducing pulmonary vascular hyperpermeability, FX06 is supposed to lead to improved lung function and reduced time of mechanical ventilation.

R&D:Systemic capillary leak Syndrome, Acute Respiratory Distress Syndrome, Localised organ damage